14. März 2018
LEA2 MPS Panel Our first LEA2 (Lysosomal Enzyme Activity) assay has now been started and with it several mucopolysaccharidoses...Read more
14. März 2018
Our awarded work (Poster Finalist at MSACL Europe, also see the PDF Poster Hemoglobinopathies_MSACL) on hemoglobinopathies and thalassemias is now...Read more
7. März 2018
The parallel measurement of lyso-GL-3 (lyso-Gb3) for Fabry disease is of high importance particularly for potential female Fabry patients,...Read more
21. November 2017
The 21st of November 2017 is ARCHIMEDlife´s 5th anniversary, a proof that out of an idea you can evolve...Read more
12. November 2017
You can easily subscribe to our bi-monthly ARCHIMEDlife Newsletter and read about laboratory diagnostics, research studies, scientific publications and...Read more
6. November 2017
We took part in the 12th Asia-Pacific Conference on Human Genetics “Genomic Medicine and Clinical Practice” from 8th to...Read more
16. Oktober 2017
Pharmaboardroom.com interviewed ARCHIMEDlife CEO David Kasper for their latest Austria issue of „Healthcare and Life Sciences Review”. Find out...Read more
26. September 2017
ARCHIMEDlife founder Assoc. Prof. DI DDr. David C. Kasper in an interview about the correct diagnosis of Morbus Fabry...Read more
13. September 2017
We are proud to be a regular part of MSACL – this year in Salzburg from 10.- 14. September...Read more
Started in 2013, ARCHIMEDlife is an independent highly-innovative company dedicated in providing and developing diagnostic services from Inborn Errors of Metabolism to Oncological Diseases. Our commitment is to provide better and faster high-quality laboratory tests for you and your family.
Our diagnostic laboratory is offering services from Clinical Mass Spectrometry to Next-Generation Sequencing. We have international collaborations with physicians, clinical researchers and industry specialized in personalized health care.
We are dedicated to the development of novel laboratory tests to to make actionable health information accessible at the time it matters.